Diabetic ketoacidosis is a worrying complication associated with the use of sodium/glucose cotransporter 2 (SGLT2) inhibitors in patients with type 1 diabetes mellitus (T1DM) or T2DM. A recent ...

1,2 Case reports have suggested that SGLT2 inhibitors may be associated with an increased risk of diabetic ketoacidosis, which led to a warning from the Food and Drug Administration (FDA ...

The euglycemic diabetic ketoacidosis (DKA) that has recently been associated with the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors will probably turn out to be very infrequent in ...

Use of sodium-glucose cotransporter 2 (SGLT2) inhibitors during acute COVID-19 illness raises the risk for euglycemic diabetic ketoacidosis (euDKA), a new case series suggests.. Five patients with ...

The incidence of diabetic ketoacidosis in patients with type 2 diabetes taking an SGLT2 inhibitor is no greater than the low levels occurring in the general diabetes population, according to a ...

Among the patients with SGLT2 inhibitor-associated DKA and ketosis (mean age 62, 54.1% men) included in the analysis, mean body mass index was 27.5 compared with 24.5 for the 20 patients with type ...

A search of the FDA Adverse Event Reporting System (FAERS) database identified 20 cases of acidosis reported as diabetic ketoacidosis (DKA), ketoacidosis, or ketosis in patients treated with SGLT2 ...

At least two studies presented here at the annual meeting of the American Association of Clinical Endocrinologists have found a connection between the SGLT2 inhibitors and diabetic ketoacidosis (DKA).

(UPDATED) The use of sodium-glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes is associated with more than a twofold increased risk of lower-limb amputations, as well as ...

For 34,671 patients who underwent one of 13 emergency surgeries, the adjusted incidence of diabetic ketoacidosis was 3.8% for ...

The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, a serious condition where the ...